Decitabine
| Evidence Level: L5 | Predicted Indications: 52 |
Quick Overview
| Item | Value |
|---|---|
| Drug Name | Decitabine |
| DrugBank ID | DB01262 |
| Brand Names (EU) | Dacogen, Inaqovi |
| Evidence Level | L5 |
| Predicted Indications | 52 |
| Top Prediction Score | 99.56% |
Approved Indication (EMA)
Inaqovi is indicated as monotherapy for the treatment of adult patients with newly diagnosed acute myeloid leukaemia (AML) who are ineligible for standard induction chemotherapy.
Predicted New Indications
TxGNN model predictions for potential drug repurposing:
| Rank | Indication | Score | Source |
|---|---|---|---|
| 1 | myeloid leukemia | 99.56% | DL |
| 2 | refractory cytopenia of childhood | 99.03% | DL |
| 3 | acute myeloid leukemia with t(8;21)(q22;q22) translocation | 99.02% | DL |
| 4 | unclassified myelodysplastic syndrome | 98.95% | DL |
| 5 | acute myeloid leukemia with inv3(p21;q26.2) or t(3;3)(p21;q26.2) | 98.95% | DL |
| 6 | acute myeloid leukemia with CEBPA somatic mutations | 98.93% | DL |
| 7 | partial deletion of the long arm of chromosome 5 | 98.86% | DL |
| 8 | myelodysplastic syndrome | 98.81% | DL |
| 9 | aregenerative anemia | 98.77% | DL |
| 10 | bulbar polio | 98.76% | DL |
| 11 | severe congenital hypochromic anemia with ringed sideroblasts | 98.63% | DL |
| 12 | 5q35 microduplication syndrome | 98.19% | DL |
| 13 | upper aerodigestive tract neoplasm | 97.69% | DL |
| 14 | neuralgic amyotrophy | 95.94% | DL |
| 15 | amyotrophic neuralgia | 95.46% | DL |
| 16 | Richter syndrome | 93.73% | DL |
| 17 | acute myeloid leukemia with t(8;16)(p11;p13) translocation | 93.26% | DL |
| 18 | acute lymphoblastic/lymphocytic leukemia | 92.74% | DL |
| 19 | acute myeloid leukemia with minimal differentiation | 92.54% | DL |
| 20 | acute myeloid leukemia with t(9;11)(p22;q23) | 92.06% | DL |
Showing top 20 of 52 predictions.
About TxGNN Predictions
Prediction Sources
| Source | Description |
|---|---|
| KG | Knowledge Graph - Network topology-based associations |
| DL | Deep Learning - Neural network score prediction |
Evidence Levels
| Level | Definition |
|---|---|
| L1 | Multiple Phase 3 RCTs / Systematic Reviews |
| L2 | Single RCT or multiple Phase 2 trials |
| L3 | Observational studies / Large case series |
| L4 | Preclinical / Mechanistic / Case reports |
| L5 | AI prediction only (current) |
Clinical Validation Needed
Research Use Only: These predictions are computational hypotheses that require clinical validation. They should NOT be used for clinical decision-making.
Next Steps for Validation
- Literature Review: Search PubMed for existing evidence
- Clinical Trial Search: Check ClinicalTrials.gov for ongoing studies
- Mechanistic Analysis: Evaluate biological plausibility
- Preclinical Studies: Conduct in vitro/in vivo validation
- Clinical Trials: Design and conduct human studies
Data Access
- FHIR API:
/fhir/ClinicalUseDefinition/ - CSV Download: All Predictions
- GitHub: yao-care/EuTxGNN
Citation
If using this data, please cite:
@article{huang2023txgnn,
title={A foundation model for clinician-centered drug repurposing},
author={Huang, Kexin and others},
journal={Nature Medicine},
year={2023},
doi={10.1038/s41591-023-02233-x}
}
Disclaimer: This report is for research purposes only and does not constitute medical advice. Drug repurposing predictions require rigorous clinical validation before any therapeutic application.